GlassScriptPhysician profile
Christine Michael
NPI 1053748053
$11,371.16
in general payments reported to CMS, 2019-2025
46 companies · $2,048 in 2025
The $2,048 reported for 2025 was more than what 96% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $787 · 2020: $1,191 · 2021: $1,780 · 2022: $1,590 · 2023: $1,369 · 2024: $2,606 · 2025: $2,048.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,023.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,022.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,031.30 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $1,593.13 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $1,310.72 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Abbvie INC. | $1,301.59 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $710.29 | 2019-2025 | Jardiance |
| Exact Sciences Corporation | $400.65 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Amarin Pharma, INC. | $390.30 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $320.90 | 2021-2025 | |
| Amgen INC. | $306.10 | 2020-2025 | Repatha, Otezla, Repatha |
| Kowa Pharmaceuticals America, INC. | $279.51 | 2019-2022 | |
| Pfizer INC. | $253.51 | 2019-2025 | |
| Teva Pharmaceuticals USA, INC. | $248.21 | 2019-2025 | Ajovy, Austedo Xr, Austedo Xr |
| Merck Sharp & Dohme LLC | $199.39 | 2019-2025 | Capvaxive, Gardasil 9, Steglatro |
| Abbott Laboratories | $194.08 | 2022-2024 | Freestyle Libre 3 |
| Phathom Pharmaceuticals, INC. | $177.26 | 2024-2025 | Voquezna |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christine Michael listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.